Title: Serum O-glycosylated hepatitis B surface antigen levels in patients with chronic hepatitis
B during nucleos(t)ide analog therapy
Version: 2 Date: 01 May 2022
Reviewer's report:
This is a very detailed and integrated supplement. Every question I concerned has been well
explained. After modification, this manuscript has been logically complete and has good clinical
value. The serum O-glycosylated HBsAg might be a potential biomarker for monitoring safe
discontinuation of NA therapy similar to the serum HBV RNA. It is worthy of academic
discussion.
Title: Serum O-glycosylated hepatitis B surface antigen levels in patients with chronic hepatitis
B during nucleos(t)ide analog therapy
Version: 2 Date: 01 May 2022
Reviewer's report:
This is a very detailed and integrated supplement. Every question I concerned has been well
explained. After modification, this manuscript has been logically complete and has good clinical
value. The serum O-glycosylated HBsAg might be a potential biomarker for monitoring safe
discontinuation of NA therapy similar to the serum HBV RNA. It is worthy of academic
discussion.
Please review this paper.
user
Title: Serum O-glycosylated hepatitis B surface antigen levels in patients with chronic hepatitis
B during nucleos(t)ide analog therapy
Version: 2 Date: 01 May 2022
Reviewer's report:
This is a very detailed and integrated supplement. Every question I concerned has been well
explained. After modification, this manuscript has been logically complete and has good clinical
value. The serum O-glycosylated HBsAg might be a potential biomarker for monitoring safe
discontinuation of NA therapy similar to the serum HBV RNA. It is worthy of academic
discussion.
assistant